This is an external link. Click “OK” to continue.
Professor, Biological Sciences & Vice President of Research (Interim) University of Calgary, Canada
Dr. Buret is a professor and scientist focused on infectious and inflammatory disorders of the pulmonary system and gastrointestinal tract.
A professor of biological sciences at the University of Calgary for 25 years, he was recently appointed Vice President of Research (Interim) for the university.
PhD Pathophysiology of Infectious Diseases University of Calgary, Canada
BSc University of Neuchatel, Switzerland
Co-founder of the renowned Inflammation Research Network at the University of Calgary, Dr. Buret has received numerous teaching and research awards. He has also been inducted into the Order of the University of Calgary, the institution’s top honor.
“We need better treatments for inflammation—solutions that don’t put the digestive system at risk.”
Professor Emeritus, Molecular and Medical Pharmacology University of California Los Angeles School of Medicine, USA
PhD Pharmacology University of Minnesota, USA
Dr. Ignarro was awarded the Nobel Prize in Physiology or Medicine for identifying the first gasotransmitter, nitric oxide. He is also the recipient of the Basic Research Prize from the American Heart Association.
“John Wallace’s insight into hydrogen sulfide’s anti-inflammatory potential is destined to change how we treat pain.”
Professor of Pharmacology School of Medicine, University of Naples, Federico II, Italy
PhD Pharmacology University of Naples, Italy
Dr. Cirino is a leading researcher in inflammation pharmacology, with more than 300 peer-reviewed articles and several book chapters.
“Delving deeper into corticosteroids has reinforced my view that there must be a safer way to tackle unwanted inflammation.”
Professor, Pathology and Director, Comparative Pathology and Medicine; Co-Director, Program in Mucosal Immunology, Allergy, & Vaccine Development University of California at San Diego, Chiba Medical School, USA
DVM (Doctor of Veterinary Medicine) University of Guelph, Canada
Dr Ernst defined many unique aspects of mucosal immunology in the gastrointestinal tract and has made significant discoveries related to the role of the microbiota in colitis. He was the first to identify two novel receptors for H. pylori and Gram negative bacteria and their connection to inflammation, oxidative stress and DNA damage.
Professor and Head, Dept. of Experimental and Translational Medicine, Scientific Director, Division of Medicine University College London, UK
PhD Pharmacology William Harvey Research Institute, University of London, UK
Dr. Gilroy is a recipient of the Novartis Award from the British Pharmacological Society, and the Bayer International Young Investigator Award for Aspirin Research. He studied under Sir John Vane (Nobel Laureate) at Wellcome Research Laboratories, UK.
“The identification of hydrogen sulfide’s role in resolving inflammation is a major advance in a field that has seen little therapeutic progress in the last 50 years.”
Professor Emeritus, Medicine and Gastroenterology McMaster University, Canada
MB ChB (Medical Degree) University of Edinburgh, UK
Dr. Hunt’s awards include the Gilbert Blane Medal of the Royal Colleges of Physicians and Surgeons of London, and the Bockus Medal of the World Gastroenterology Association. He has also been inducted into the McMaster University Community of Distinction.
“Antibe is building an important new drug platform that will serve a large and serious unmet medical need.”
|Department Head and Professor, Pharmacology, Therapeutics and Biomedical Sciences University of São Paulo, Brazil
Professor, Pharmacology School of Medical Sciences, State University of Campinas and Camilo Castelo Branco University, Brazil
As a medical doctor and scientist, Dr. de Nucci’s research focuses on the pharmacology of inflammation and cardiovascular disease.
He founded the Cartesius Analytical Unit, an organization that provides drug quality reviews for the licensing of generic medications in Brazil. He also established the Galeno Research Center for clinical trials.
|MD Medical School of Ribeirão Preto, University of São Paulo, Brazil
PhD Pharmacology University of London, UK
Postdoctoral studies at Wellcome Research Laboratories, UK
Dr. de Nucci has published more than 500 scientific papers and other scientific works. He studied under Sir John Vane (Nobel Laureate) and Sir Salvador Moncada at Wellcome Research Laboratories in the UK.
“The promise of hydrogen sulfide is profound.”
President University of Texas Southwestern Medical Center, USA
MD Harvard Medical School, USA
Dr. Podolsky is a recipient of the Julius Friedenwald Medal and the Distinguished Achievement Award, both from the American Gastroenterological Association. He is also a past recipient of the Merit Award from the National Institutes of Health.
“The opioid crisis has vastly increased the need and urgency for safer, non-addictive pain therapeutics.”
Alfred Gilman Professor and Vice Chairman, Pharmacology and Cardiology, and Director, Vascular Biology & Therapeutics Yale School of Medicine, USA
PhD Pharmacology New York Medical College, USA
Dr Sessa is an inaugural recipient of the Merit Award from the American Heart Association. He has also received the highest award of distinction from the North American Vascular Biology Organization in recognition of his work on the production and regulation of nitric oxide in the vasculature.
“As we age, the body’s inflammation responses become increasingly counterproductive. Antibe’s research suggests that hydrogen sulfide can play a significant protective role.”
Professor and Canada Research Chair, Paediatrics, Microbiology, Laboratory Medicine and Pathobiology, Nutritional Sciences & Dentistry The Hospital for Sick Children, University of Toronto, Canada
MD University of Toronto Medical School, Canada
Dr. Sherman is a recipient of the Distinguished Service Award and the Physician Research Award for Career Excellence from the Canadian Association of Gastroenterology. Hepatology, and Nutrition.
“Particularly in children, pain management presents clinicians with a challenging set of trade-offs. Antibe’s research suggests that there are better alternatives on the horizon.”